Industry Research Reports

Home > Reports > Medical Devices & Consumables > Rare Hematology - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Rare Hematology - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Medical Devices & Consumables

Published: 2024-01-16

Pages: 113 Pages

Report ld: 2228224

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

The global market for Rare Hematology was estimated to be worth US$ 13700 million in 2023 and is forecast to a readjusted size of US$ 18360 million by 2030 with a CAGR of 4.2% during the forecast period 2024-2030
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

Rare Hematology Market Size

M= millions and B=billions

Report Scope
This report aims to provide a comprehensive presentation of the global market for Rare Hematology, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Rare Hematology by region & country, by Type, and by Application.

The Rare Hematology market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rare Hematology.

Market Segmentation

Report Metric
Details
Report Title
Rare Hematology - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Forecasted Market Size in 2030
US$ 18360 million
CAGR(2024-2030)
4.2%
Market Size Available for Years
2019-2030
Global Rare Hematology Companies Covered
Takeda, Novo Nordisk A/S, Pfizer Inc., Bayer Healthcare AG, CSL Behring LLC, Biogen Inc., Alexion Pharmaceuticals, Celgene Corporation, Amgen Inc., PRA Health Sciences
Global Rare Hematology Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Rare Hematology Market, Segment by Type
Recombinant Factors

Plasma Derived Factors
Global Rare Hematology Market, Segment by Application
Pediatric

Adult
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Rare Hematology manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Rare Hematology in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Rare Hematology in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Rare Hematology Product Introduction
    1.2 Global Rare Hematology Market Size Forecast
    1.3 Rare Hematology Market Trends & Drivers
        1.3.1 Rare Hematology Industry Trends
        1.3.2 Rare Hematology Market Drivers & Opportunity
        1.3.3 Rare Hematology Market Challenges
        1.3.4 Rare Hematology Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Rare Hematology Players Revenue Ranking (2023)
    2.2 Global Rare Hematology Revenue by Company (2019-2024)
    2.3 Key Companies Rare Hematology Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Rare Hematology Product Offered
    2.5 Key Companies Time to Begin Mass Production of Rare Hematology
    2.6 Rare Hematology Market Competitive Analysis
        2.6.1 Rare Hematology Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Rare Hematology Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rare Hematology as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Recombinant Factors
        3.1.2 Plasma Derived Factors
    3.2 Global Rare Hematology Sales Value by Type
        3.2.1 Global Rare Hematology Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Rare Hematology Sales Value, by Type (2019-2030)
        3.2.3 Global Rare Hematology Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Pediatric
        4.1.2 Adult
    4.2 Global Rare Hematology Sales Value by Application
        4.2.1 Global Rare Hematology Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Rare Hematology Sales Value, by Application (2019-2030)
        4.2.3 Global Rare Hematology Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Rare Hematology Sales Value by Region
        5.1.1 Global Rare Hematology Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Rare Hematology Sales Value by Region (2019-2024)
        5.1.3 Global Rare Hematology Sales Value by Region (2025-2030)
        5.1.4 Global Rare Hematology Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Rare Hematology Sales Value, 2019-2030
        5.2.2 North America Rare Hematology Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Rare Hematology Sales Value, 2019-2030
        5.3.2 Europe Rare Hematology Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Rare Hematology Sales Value, 2019-2030
        5.4.2 Asia Pacific Rare Hematology Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Rare Hematology Sales Value, 2019-2030
        5.5.2 South America Rare Hematology Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Rare Hematology Sales Value, 2019-2030
        5.6.2 Middle East & Africa Rare Hematology Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Rare Hematology Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Rare Hematology Sales Value
    6.3 United States
        6.3.1 United States Rare Hematology Sales Value, 2019-2030
        6.3.2 United States Rare Hematology Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Rare Hematology Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Rare Hematology Sales Value, 2019-2030
        6.4.2 Europe Rare Hematology Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Rare Hematology Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Rare Hematology Sales Value, 2019-2030
        6.5.2 China Rare Hematology Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Rare Hematology Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Rare Hematology Sales Value, 2019-2030
        6.6.2 Japan Rare Hematology Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Rare Hematology Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Rare Hematology Sales Value, 2019-2030
        6.7.2 South Korea Rare Hematology Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Rare Hematology Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Rare Hematology Sales Value, 2019-2030
        6.8.2 Southeast Asia Rare Hematology Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Rare Hematology Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Rare Hematology Sales Value, 2019-2030
        6.9.2 India Rare Hematology Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Rare Hematology Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Takeda
        7.1.1 Takeda Profile
        7.1.2 Takeda Main Business
        7.1.3 Takeda Rare Hematology Products, Services and Solutions
        7.1.4 Takeda Rare Hematology Revenue (US$ Million) & (2019-2024)
        7.1.5 Takeda Recent Developments
    7.2 Novo Nordisk A/S
        7.2.1 Novo Nordisk A/S Profile
        7.2.2 Novo Nordisk A/S Main Business
        7.2.3 Novo Nordisk A/S Rare Hematology Products, Services and Solutions
        7.2.4 Novo Nordisk A/S Rare Hematology Revenue (US$ Million) & (2019-2024)
        7.2.5 Novo Nordisk A/S Recent Developments
    7.3 Pfizer Inc.
        7.3.1 Pfizer Inc. Profile
        7.3.2 Pfizer Inc. Main Business
        7.3.3 Pfizer Inc. Rare Hematology Products, Services and Solutions
        7.3.4 Pfizer Inc. Rare Hematology Revenue (US$ Million) & (2019-2024)
        7.3.5 Bayer Healthcare AG Recent Developments
    7.4 Bayer Healthcare AG
        7.4.1 Bayer Healthcare AG Profile
        7.4.2 Bayer Healthcare AG Main Business
        7.4.3 Bayer Healthcare AG Rare Hematology Products, Services and Solutions
        7.4.4 Bayer Healthcare AG Rare Hematology Revenue (US$ Million) & (2019-2024)
        7.4.5 Bayer Healthcare AG Recent Developments
    7.5 CSL Behring LLC
        7.5.1 CSL Behring LLC Profile
        7.5.2 CSL Behring LLC Main Business
        7.5.3 CSL Behring LLC Rare Hematology Products, Services and Solutions
        7.5.4 CSL Behring LLC Rare Hematology Revenue (US$ Million) & (2019-2024)
        7.5.5 CSL Behring LLC Recent Developments
    7.6 Biogen Inc.
        7.6.1 Biogen Inc. Profile
        7.6.2 Biogen Inc. Main Business
        7.6.3 Biogen Inc. Rare Hematology Products, Services and Solutions
        7.6.4 Biogen Inc. Rare Hematology Revenue (US$ Million) & (2019-2024)
        7.6.5 Biogen Inc. Recent Developments
    7.7 Alexion Pharmaceuticals
        7.7.1 Alexion Pharmaceuticals Profile
        7.7.2 Alexion Pharmaceuticals Main Business
        7.7.3 Alexion Pharmaceuticals Rare Hematology Products, Services and Solutions
        7.7.4 Alexion Pharmaceuticals Rare Hematology Revenue (US$ Million) & (2019-2024)
        7.7.5 Alexion Pharmaceuticals Recent Developments
    7.8 Celgene Corporation
        7.8.1 Celgene Corporation Profile
        7.8.2 Celgene Corporation Main Business
        7.8.3 Celgene Corporation Rare Hematology Products, Services and Solutions
        7.8.4 Celgene Corporation Rare Hematology Revenue (US$ Million) & (2019-2024)
        7.8.5 Celgene Corporation Recent Developments
    7.9 Amgen Inc.
        7.9.1 Amgen Inc. Profile
        7.9.2 Amgen Inc. Main Business
        7.9.3 Amgen Inc. Rare Hematology Products, Services and Solutions
        7.9.4 Amgen Inc. Rare Hematology Revenue (US$ Million) & (2019-2024)
        7.9.5 Amgen Inc. Recent Developments
    7.10 PRA Health Sciences
        7.10.1 PRA Health Sciences Profile
        7.10.2 PRA Health Sciences Main Business
        7.10.3 PRA Health Sciences Rare Hematology Products, Services and Solutions
        7.10.4 PRA Health Sciences Rare Hematology Revenue (US$ Million) & (2019-2024)
        7.10.5 PRA Health Sciences Recent Developments

 8 Industry Chain Analysis
    8.1 Rare Hematology Industrial Chain
    8.2 Rare Hematology Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Rare Hematology Sales Model
        8.5.2 Sales Channel
        8.5.3 Rare Hematology Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Rare Hematology Market Trends
    Table 2. Rare Hematology Market Drivers & Opportunity
    Table 3. Rare Hematology Market Challenges
    Table 4. Rare Hematology Market Restraints
    Table 5. Global Rare Hematology Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Rare Hematology Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Rare Hematology Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Rare Hematology Product Type
    Table 9. Key Companies Time to Begin Mass Production of Rare Hematology
    Table 10. Global Rare Hematology Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rare Hematology as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Rare Hematology Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Rare Hematology Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Rare Hematology Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Rare Hematology Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Rare Hematology Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Rare Hematology Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Rare Hematology Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Rare Hematology Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Rare Hematology Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Rare Hematology Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Rare Hematology Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Rare Hematology Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Rare Hematology Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Rare Hematology Sales Value by Region (2019-2024) & (%)
    Table 27. Global Rare Hematology Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Rare Hematology Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Rare Hematology Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Rare Hematology Sales Value, (2025-2030) & (US$ Million)
    Table 31. Takeda Basic Information List
    Table 32. Takeda Description and Business Overview
    Table 33. Takeda Rare Hematology Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Rare Hematology Business of Takeda (2019-2024)
    Table 35. Takeda Recent Developments
    Table 36. Novo Nordisk A/S Basic Information List
    Table 37. Novo Nordisk A/S Description and Business Overview
    Table 38. Novo Nordisk A/S Rare Hematology Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Rare Hematology Business of Novo Nordisk A/S (2019-2024)
    Table 40. Novo Nordisk A/S Recent Developments
    Table 41. Pfizer Inc. Basic Information List
    Table 42. Pfizer Inc. Description and Business Overview
    Table 43. Pfizer Inc. Rare Hematology Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Rare Hematology Business of Pfizer Inc. (2019-2024)
    Table 45. Pfizer Inc. Recent Developments
    Table 46. Bayer Healthcare AG Basic Information List
    Table 47. Bayer Healthcare AG Description and Business Overview
    Table 48. Bayer Healthcare AG Rare Hematology Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Rare Hematology Business of Bayer Healthcare AG (2019-2024)
    Table 50. Bayer Healthcare AG Recent Developments
    Table 51. CSL Behring LLC Basic Information List
    Table 52. CSL Behring LLC Description and Business Overview
    Table 53. CSL Behring LLC Rare Hematology Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Rare Hematology Business of CSL Behring LLC (2019-2024)
    Table 55. CSL Behring LLC Recent Developments
    Table 56. Biogen Inc. Basic Information List
    Table 57. Biogen Inc. Description and Business Overview
    Table 58. Biogen Inc. Rare Hematology Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Rare Hematology Business of Biogen Inc. (2019-2024)
    Table 60. Biogen Inc. Recent Developments
    Table 61. Alexion Pharmaceuticals Basic Information List
    Table 62. Alexion Pharmaceuticals Description and Business Overview
    Table 63. Alexion Pharmaceuticals Rare Hematology Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Rare Hematology Business of Alexion Pharmaceuticals (2019-2024)
    Table 65. Alexion Pharmaceuticals Recent Developments
    Table 66. Celgene Corporation Basic Information List
    Table 67. Celgene Corporation Description and Business Overview
    Table 68. Celgene Corporation Rare Hematology Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Rare Hematology Business of Celgene Corporation (2019-2024)
    Table 70. Celgene Corporation Recent Developments
    Table 71. Amgen Inc. Basic Information List
    Table 72. Amgen Inc. Description and Business Overview
    Table 73. Amgen Inc. Rare Hematology Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Rare Hematology Business of Amgen Inc. (2019-2024)
    Table 75. Amgen Inc. Recent Developments
    Table 76. PRA Health Sciences Basic Information List
    Table 77. PRA Health Sciences Description and Business Overview
    Table 78. PRA Health Sciences Rare Hematology Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Rare Hematology Business of PRA Health Sciences (2019-2024)
    Table 80. PRA Health Sciences Recent Developments
    Table 81. Key Raw Materials Lists
    Table 82. Raw Materials Key Suppliers Lists
    Table 83. Rare Hematology Downstream Customers
    Table 84. Rare Hematology Distributors List
    Table 85. Research Programs/Design for This Report
    Table 86. Key Data Information from Secondary Sources
    Table 87. Key Data Information from Primary Sources
    Table 88. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Rare Hematology Product Picture
    Figure 2. Global Rare Hematology Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Rare Hematology Sales Value (2019-2030) & (US$ Million)
    Figure 4. Rare Hematology Report Years Considered
    Figure 5. Global Rare Hematology Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Rare Hematology Revenue in 2023
    Figure 7. Rare Hematology Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Recombinant Factors Picture
    Figure 9. Plasma Derived Factors Picture
    Figure 10. Global Rare Hematology Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 11. Global Rare Hematology Sales Value Market Share by Type, 2023 & 2030
    Figure 12. Product Picture of Pediatric
    Figure 13. Product Picture of Adult
    Figure 14. Global Rare Hematology Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 15. Global Rare Hematology Sales Value Market Share by Application, 2023 & 2030
    Figure 16. North America Rare Hematology Sales Value (2019-2030) & (US$ Million)
    Figure 17. North America Rare Hematology Sales Value by Country (%), 2023 VS 2030
    Figure 18. Europe Rare Hematology Sales Value (2019-2030) & (US$ Million)
    Figure 19. Europe Rare Hematology Sales Value by Country (%), 2023 VS 2030
    Figure 20. Asia Pacific Rare Hematology Sales Value (2019-2030) & (US$ Million)
    Figure 21. Asia Pacific Rare Hematology Sales Value by Country (%), 2023 VS 2030
    Figure 22. South America Rare Hematology Sales Value (2019-2030) & (US$ Million)
    Figure 23. South America Rare Hematology Sales Value by Country (%), 2023 VS 2030
    Figure 24. Middle East & Africa Rare Hematology Sales Value (2019-2030) & (US$ Million)
    Figure 25. Middle East & Africa Rare Hematology Sales Value by Country (%), 2023 VS 2030
    Figure 26. Key Countries/Regions Rare Hematology Sales Value (%), (2019-2030)
    Figure 27. United States Rare Hematology Sales Value, (2019-2030) & (US$ Million)
    Figure 28. United States Rare Hematology Sales Value by Type (%), 2023 VS 2030
    Figure 29. United States Rare Hematology Sales Value by Application (%), 2023 VS 2030
    Figure 30. Europe Rare Hematology Sales Value, (2019-2030) & (US$ Million)
    Figure 31. Europe Rare Hematology Sales Value by Type (%), 2023 VS 2030
    Figure 32. Europe Rare Hematology Sales Value by Application (%), 2023 VS 2030
    Figure 33. China Rare Hematology Sales Value, (2019-2030) & (US$ Million)
    Figure 34. China Rare Hematology Sales Value by Type (%), 2023 VS 2030
    Figure 35. China Rare Hematology Sales Value by Application (%), 2023 VS 2030
    Figure 36. Japan Rare Hematology Sales Value, (2019-2030) & (US$ Million)
    Figure 37. Japan Rare Hematology Sales Value by Type (%), 2023 VS 2030
    Figure 38. Japan Rare Hematology Sales Value by Application (%), 2023 VS 2030
    Figure 39. South Korea Rare Hematology Sales Value, (2019-2030) & (US$ Million)
    Figure 40. South Korea Rare Hematology Sales Value by Type (%), 2023 VS 2030
    Figure 41. South Korea Rare Hematology Sales Value by Application (%), 2023 VS 2030
    Figure 42. Southeast Asia Rare Hematology Sales Value, (2019-2030) & (US$ Million)
    Figure 43. Southeast Asia Rare Hematology Sales Value by Type (%), 2023 VS 2030
    Figure 44. Southeast Asia Rare Hematology Sales Value by Application (%), 2023 VS 2030
    Figure 45. India Rare Hematology Sales Value, (2019-2030) & (US$ Million)
    Figure 46. India Rare Hematology Sales Value by Type (%), 2023 VS 2030
    Figure 47. India Rare Hematology Sales Value by Application (%), 2023 VS 2030
    Figure 48. Rare Hematology Industrial Chain
    Figure 49. Rare Hematology Manufacturing Cost Structure
    Figure 50. Channels of Distribution (Direct Sales, and Distribution)
    Figure 51. Bottom-up and Top-down Approaches for This Report
    Figure 52. Data Triangulation

Description

The global market for Rare Hematology was estimated to be worth US$ 13700 million in 2023 and is forecast to a readjusted size of US$ 18360 million by 2030 with a CAGR of 4.2% during the forecast period 2024-2030
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Rare Hematology, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Rare Hematology by region & country, by Type, and by Application.

The Rare Hematology market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rare Hematology.

Market Segmentation